Validation of an immunohistochemical signature predictive of 8-year outcome for patients with breast carcinoma

International Journal of Cancer

Volumn 131, Issue 3, 2012, Pages

  Charpin, Colette ^a   Tavassoli, Fattaneh ^b   Secq, Véronique ^a   Giusiano, Sophie ^a   Villeret, Julia ^a   Garcia, Stéphane ^a   Birnbaum, Daniel ^c   Bonnier, Pascal ^d   Lavaut, Marie Noëlle ^a   Boubli, Léon ^d   Carcopino, Xavier ^d   Iovanna, Juan ^a  

^a HÔPITAL NORD   (France)

^b YALE UNIVERSITY   (United States)

^c AIX MARSEILLE UNIVERSITY   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

breast carcinoma; prognostic signature; quantitative immunohistochemistry

Indexed keywords

AFADIN; ALDEHYDE DEHYDROGENASE; CD24 ANTIGEN; CLAUDIN 1; CYTOKERATIN 5; CYTOKERATIN 6; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MOESIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SHARP2; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; COHORT ANALYSIS; CORRELATION ANALYSIS; DENSITOMETRY; FRANCE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; UNIVERSITY HOSPITAL;

AGED; BREAST NEOPLASMS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KINESIN; MEMBRANE PROTEINS; MIDDLE AGED; MYOSINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR MARKERS, BIOLOGICAL;

EID: 84861578696     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27371     Document Type: Article

References (44)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel Members,. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2005; 16: 1569-83.
3. NCCN Clinical Practice Guidelines in Oncology. Available at: www.nccn.org, 2007
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
5. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 2002; 347: 1999-2009.
6. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23.
8. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004; 64: 8558-65.
9. Pittman J, Huang E, Dressman H, Horng CF, Cheng SH, Tsou MH, Chen CM, Bild A, Iversen ES, Huang AT, Nevins JR, West M,. Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci USA 2004; 101: 8431-6.
10. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102: 3738-43.
11. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 2004; 351: 2817-26.
12. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-92.
13. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-9.
14. Dunkler D, Michiels S, Schemper M,. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 2007; 43: 745-51.
15. Michiels S, Koscielny S, Hill C,. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365: 488-92.
16. Simon R, Radmacher MD, Dobbin K, McShane LM,. Pitfalls in the use of DNA microarray data for diagnosis and prognostic classification. J Natl Cancer Inst 2003; 95: 14-8.
17. Camp RL, Chung GG, Rimm DL,. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8: 1323-7.
18. Emerson JW, Dolled-Filhart M, Harris L, Rimm DL, Tuck DP,. Quantitative assessment of tissue biomarkers and construction of a model to predict outcome in breast cancer using multiple imputation. Cancer Inform 2009; 7: 29-40.
19. Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL,. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 2007; 87: 662-9.
20. Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL,. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumour heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 2007; 25: 5418-25.
21. Pozner-Moulis S, Cregger M, Camp RL, Rimm DL,. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest 2007; 87: 251-60.
22. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S,. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 2009; 124: 2124-34.
23. Giusiano S, Secq V, Carcopino X, Carpentier S, Andrac l, Lavaut MN, Allasia C, Bonnier P, Iovanna JL, Garcia S, Boubli L, Birnbaum D, Charpin C,. Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk. Int J Oncol 2010; 36: 889-98.
24. Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, Gilks CB,. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004; 10: 6143-51.
25. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
26. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005; 65: 767-79.
27. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F,. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006; 25: 2273-84.
28. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM,. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-71.
29. Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, Cervera N, Geneix J, Hassanein M, Rabayrol L, Sobol H, Taranger-Charpin C, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer 2007; 121: 1779-85.
30. Da Silva L, Clarke C, Lakhani SR,. Demystifying basal-like breast carcinomas. J Clin Pathol 2007; 60: 1328-32.
31. Reis-Filho JS, Tutt AN,. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-18.
32. Royston P, Douglas G, Sauerbrei A,. Dichotomising continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25: 127-41.
33. Altman DG, Lausen B, Sauerbrei W, Schumacher M,. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-35.
34. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP,. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.
35. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP,. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-9.
36. Darb-Esfahani S, Faggad A, Noske, Weichert W, Buckendahl AC, Muller B, Budczies J, Roske A, Dietel M, Denker C,. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma:association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 2009; 135: 933-41.
37. Rao RD, Buckner JC, Sarkaria JN,. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 2004; 4: 621-35.
38. Boulay A, Rudloff J, Ye Y, Zumstein-Mecker S,. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11: 5319-28.
39. Pouyssegur J, Dayan F, Mazure NM,. Hypoxia signaling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-43.
40. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C,. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005; 116: 734-9.
41. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C,. Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905). Br J Cancer 2004; 90: 1216-21.
42. Gort EH, Groot AJ, Derks van de Ven TLP, van der Groep P, Verlaan I, van Laar T, van Diest PJ, van der Wall E, Shvartz A,. Hypoxia-inducible factor-1α expression requires PI 3-kinase activity and correlates with AKT1 phosphorylation in invasive breast carcinomas. Oncogene 2006; 25: 6123-7.
43. Helczynska K, Larsson A-M, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S, Jirstrom K,. Hypoxia-inducible factor-2α correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 2008; 68: 9212-20.
44. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouysségur J, Berra E,. Hif-1α and CAIX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007; 120: 1451-8.